Clinical Trials Browser

Idarubicin × 30 days × Clear all

Leukemia, Myeloid, Acute

NCT04250051 2026-06-01

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

2 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

Phase 1/2 Not yet recruiting

30 enrolled

Other hematologic neoplasm

Leukemia, Myeloid

NCT02688140 2026-05-29

TUD-APOLLO-064

Phase 3 Completed

133 enrolled

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT04214249 2026-05-28

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Phase 2 Active not recruiting

49 enrolled 32 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02632708 2026-05-22

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Phase 1 Active not recruiting

153 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Phase 2 Recruiting

100 enrolled

MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Phase 2 Recruiting

508 enrolled

MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Phase 1/2 Recruiting

36 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Clinical Trials

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

TUD-APOLLO-064

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse